SEC Tracker
Get the app

Stryker SYK

Stryker Q3 FY24: revenue $5.5B; diluted EPS $2.16

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Stryker reported for Q3 FY24, the quarter ended Sep 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$5.5BNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income$834.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS$2.16No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$3.9BNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations$1.5BNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Stryker files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Boston Scientific BSX public float $158.7B, Jun 30, 2025
  2. Medtronic MDT public float $120.1B, Oct 24, 2025
  3. Intuitive Surgical ISRG public float $193.9B, Jun 30, 2025
  4. 3M MMM public float $81.1B, Jun 30, 2025
  5. Becton Dickinson BDX public float $65.5B, Mar 31, 2025, over 18 months old